1937–1966

Open-Heart Surgery and Valve Innovations

The advent of pump-oxygenators enabled direct-vision intracardiac procedures, driving rapid advancements in valve reconstruction, cusp replacement, and aortic operations. Research expanded into congenital heart disease malformations and repair strategies to shape pediatric cardiac surgery. Postoperative management emerged as a crucial axis to mitigate embolic, leak, and infection risks while improving long-term vascular safety. Early translational imaging, catheter concepts, and diastolic balloon pumping introduced foundational precedents for circulatory support and interventional therapies.

Period 1937-1966: Pump-oxygenators and congenital models enabled direct-vision intracardiac valve operations, aortic coarctation repair, and postoperative management protocols[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Percutaneous access, angioplasty, coarctation repair, aneurysm strategies, and balloon pumping shaped endovascular therapy and circulatory support[16][17][7][18][19].

1967–1973

Diversification and Standardization of Coronary Bypass

Coronary bypass grafting consolidated as a standard angina treatment through the integration of vein grafting and left internal mammary artery conduits. Operators advanced multi-modality revascularization strategies alongside aortic replacement techniques for aneurysms and dissections. The introduction of flow-directed catheters significantly transformed perioperative monitoring and critical care safety. Early clinical experiences with orthotopic heart transplantation also initiated vital research into immunosuppression.

Period 1967-1973: Surgeons combined vein grafting, endarterectomy, and flow catheters to execute complex coronary procedures[1][2][3][4][5][6][7][8][9][10][11][12]. Internal mammary grafts, saphenous vein bypasses, aortic replacements, and heart transplants transformed cardiovascular surgery[13][14][15].

1974–2002

Percutaneous Revascularization and Surgical Standardization

Percutaneous transluminal coronary angioplasty emerged as a primary revascularization strategy, driven by comparative trials against coronary artery bypass grafting. Restenosis prompted endovascular solutions like intracoronary stents and pharmacologic strategies, while registries and guidelines standardized care and quantified complications. Standardized grading systems, echocardiographic validation, and cardiac risk indices transformed patient selection, preoperative assessment, and surgical planning. Formal guidelines for coronary artery bypass graft surgery established definitive indications, techniques, and perioperative protocols to anchor modern practice.

Period 1974-2002: Angioplasty and stenting dominated revascularization while randomized trials, registries, and guidelines standardized safety and combatting restenosis[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. Standardized grading systems, echocardiographic validation, risk indices, and bypass guidelines shaped later surgical planning and practice[19][20][21][4].

2003–2023

Transcatheter Valve and Device Revolution

Catheter-based therapies transformed cardiovascular surgery through the rapid maturation of transcatheter valve replacement and drug-eluting stents. Standardized criteria and large registries enabled rigorous comparative effectiveness research across diverse patient risk strata. Clinical trials and cross-disciplinary collaboration solidified percutaneous interventions for complex coronary and structural heart disease. Expanded device platforms and standardized outcomes reporting established transcatheter strategies as mainstream options in modern practice.

Period 2003-2009: Transcatheter valves, drug-eluting stents, and device therapy matured through imaging-guided planning and trials, expanding interventional access for high-risk patients[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. Landmark trials and databases transformed revascularization strategies, heart failure management, and prosthesis selection[16][19][20][11][21]. Period 2010-2016: Standardized endpoints[22][23][24][25][26], comparative trials[27][28][29][30][31][32], mortality analyses[33][30][34][35], registries[27][28][36][37][38], and quality metrics[39][40][38] evaluated TAVR. Landmark trials[27][41][42] and consensus criteria[22] expanded indications, catalyzed guideline updates, and shifted clinical practice. Period 2017-2023: Transcatheter valve therapies expanded across risk strata and anatomical variants, utilizing registries and standardized degeneration definitions to evaluate device platforms[43][44][45][46][47][48][49][50][51][52][53][54][55][56][57]. Landmark trials established TAVR noninferiority in low and intermediate risk cohorts, transforming heart failure and shock management guidelines[43][44][45][58][59].

Open-Heart Surgery and Valve Innovations era

S. I. Seldinger and 2 others

S. I. Seldinger[1], working at Karolinska University Hospital[4] and Stockholm South General Hospital[5], contributed to early translational imaging and catheter concepts by developing percutaneous vascular access. Through Catheter Replacement of the Needle in Percutaneous Arteriography: A new technique[9], this work established foundational precedents for interventional therapies and safe catheter handling. Melvin P. Judkins[2], associated with the University of Oregon[6] and Lund University[7], advanced catheter-based interventions for vascular safety. In Transluminal Treatment of Arteriosclerotic Obstruction[10], this research explored transluminal methods to address vascular obstructions as part of evolving catheter concepts. Charles T. Dotter[3], based at the University of Oregon[6] and Cornell University[8], furthered interventional therapies and vascular management. Through Transluminal Treatment of Arteriosclerotic Obstruction[10], this investigation pioneered transluminal treatment strategies to improve long-term vascular safety.

Diversification and Standardization of Coronary Bypass era

H. H. Bentall and A Bono

H. H. Bentall[11], working at Hammersmith Hospital[13] and London Postgraduate Medical and Dental Education[14], contributed to the era's focus on aortic replacement techniques for aneurysms and dissections. Through A technique for complete replacement of the ascending aorta[15], this work advanced multi-modality revascularization strategies alongside aortic replacement techniques for aneurysms and dissections. A Bono[12], working at Hammersmith Hospital[13] and London Postgraduate Medical and Dental Education[14], also contributed to the era's focus on aortic replacement techniques for aneurysms and dissections. Through A technique for complete replacement of the ascending aorta[15], this work advanced multi-modality revascularization strategies alongside aortic replacement techniques for aneurysms and dissections.

Percutaneous Revascularization and Surgical Standardization era

Nathaniel Reichek and R DEVEREUX

Nathaniel Reichek[16] conducted research while affiliated with the Hospital of the University of Pennsylvania[18] and Allegheny General Hospital[19], advancing echocardiographic validation through Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method[21] to transform preoperative assessment and patient selection. R DEVEREUX[17] developed further contributions at Cornell University[8] and NewYork–Presbyterian Hospital[20], utilizing the same study Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method[21] to refine cardiac risk indices and surgical planning.

Transcatheter Valve and Device Revolution era

Martin B. Leon and Michael J. Mack

Martin B. Leon[22] conducted research while affiliated with Columbia University Irving Medical Center[24] and the Cardiovascular Research Foundation[25]. Through landmark clinical investigations including Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery[28], Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients[29], Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients[30], Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients[31], Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery[32], Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement[33], Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis[34], Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials[35], Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis[36], Transcatheter Versus Surgical Aortic-Valve Replacement in High-Risk Patients[37], Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis[38], Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial[39], Health-Related Quality of Life After Transcatheter Valve Replacement in Inoperable Patients With Severe Aortic Stenosis[40], Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses[41], and Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke[42], this work drove the rapid maturation of transcatheter valve replacement, drug-eluting stents, standardized criteria, rigorous comparative effectiveness research across diverse patient risk strata, and the establishment of percutaneous interventions as mainstream options for structural heart disease. Michael J. Mack[23] advanced the field while working at Baylor Scott & White Health[26] and Heart Hospital Baylor Plano[27]. By contributing to Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery[28], Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients[29], Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients[30], Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients[31], Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease[43], Transcatheter Mitral-Valve Repair in Patients with Heart Failure[44], Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium[45], Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials[35], Transcatheter Versus Surgical Aortic-Valve Replacement in High-Risk Patients[37], 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry[46], Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial[39], Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses[41], Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke[42], and Minimally invasive transapical beating heart aortic valve implantation — proof of concept[47], this investigator solidified percutaneous and surgical options for complex coronary and structural heart disease through large registries, cross-disciplinary collaboration, and standardized outcomes reporting.